Table 1 Baseline characteristics of patient with Graves’ disease with normal liver function and liver dysfunction
From: Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
Characteristics | Total | Normal liver function (n = 288) | Liver dysfunction (n = 222) | p value |
|---|---|---|---|---|
Male (%) | 30.59 | 26.04 | 36.49 | 0.011 |
Age (years) | 41.51 ± 13.85 | 41.8 ± 14.322 | 41.13 ± 13.224 | 0.587 |
Duration of disease (years) | 4.96 ± 6.46 | 5.8 ± 6.65 | 3.9 ± 6.0 | 0.001 |
Weight (kg) | 57.67 ± 9.74 | 57.05 ± 9.01 | 58.47 ± 10.59 | 0.112 |
Heart rate (bpm) | 92.98 ± 16.7 | 92.84 ± 16.66 | 93.16 ± 16.81 | 0.830 |
Thyroid volume (ml) | 21.33 (14.75, 29.91) | 22.32 (14.34, 32.19) | 20.92 (15.32, 29.19) | 0.590 |
2-h RAIU (%) | 59.43 ± 21.44 | 58.61 ± 21.43 | 60.48 ± 21.46 | 0.328 |
6-h RAIU (%) | 78.73 ± 17.46 | 78.24 ± 17.71 | 79.36 ± 17.15 | 0.473 |
Dose of iodine (mCi) | 12.50 ± 3.07 | 12.59 ± 2.878 | 12.38 ± 3.304 | 0.433 |
TSH (mIU/l) | 0.005 (0.005, 0.01) | 0.005 (0.005, 0.010) | 0.005 (0.005, 0.010) | 0.110 |
FT3 (pmol/l) | 22.35 (15.41, 33.20) | 20.60 (12.47, 32.78) | 27.57 (17.38, 39.45) | < 0.001 |
FT4 (pmol/l) | 60.75 (38.1, 93.79) | 53.50 (35.07, 83.35) | 65.40 (44.81, 100.00) | < 0.001 |
TRAb (IU/ml) | 14.94 (7.22, 35.48) | 12.36 (5.86, 26.95) | 14.98 (7.38, 32.77) | 0.067 |
TPOAb (IU/ml) | 258.72 (57.32, 565.5) | 262.2 (47.3, 596.7) | 251.2 (82.5, 501.8) | 0.820 |
TgAb (IU/ml) | 201.4 (32.8, 541.1) | 190.9 (28.3, 508.3) | 206.3 (39.8, 554.0) | 0.453 |
ALT (U/l) | 36.2 (24.3, 54.75) | 24.00 (17.73, 31.00) | 56.55 (45.25, 80.05) | < 0.001 |
AST (U/l) | 28.5 (21.95, 39.7) | 22.35 (18.40, 26.68) | 40.45 (32.68, 51.33) | < 0.001 |
ATDs | 0.005 | |||
None | 59 | 22 | 37 | |
PTU | 100 | 60 | 40 | |
MMI | 351 | 209 | 142 |